Evidence map›Paper›PMID 28887715›Full record

ArticleBrain tumor pathology2018

Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas.

Lawrance K Chung, Panayiotis E Pelargos, Ann M Chan, Joanna V Demos, Carlito Lagman, John P Sheppard, Thien Nguyen, Yu-Ling Chang, Seyed A Hojat, Robert M Prins and 8 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Brain tumor pathology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 13 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

Lawrance K ChungDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Panayiotis E PelargosDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Ann M ChanDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, 924 Westwood Blvd, Seventh Floor, Los Angeles, CA, 90095, USA.
Joanna V DemosDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Carlito LagmanDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
John P SheppardDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Thien NguyenDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Yu-Ling ChangDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, 924 Westwood Blvd, Seventh Floor, Los Angeles, CA, 90095, USA.
Seyed A HojatDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, 924 Westwood Blvd, Seventh Floor, Los Angeles, CA, 90095, USA.
Robert M PrinsDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Linda M LiauDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA.
Leia NghiemphuDepartment of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA, 90095, USA.
Albert LaiDepartment of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA, 90095, USA.
Timothy F CloughesyDepartment of Neurology, University of California, Los Angeles, 710 Westwood Plaza, Los Angeles, CA, 90095, USA.
William H YongDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, 924 Westwood Blvd, Seventh Floor, Los Angeles, CA, 90095, USA.
Lynn K GordonDepartment of Ophthalmology, University of California, Los Angeles, 100 Stein Plaza, Los Angeles, CA, 90095, USA.
Madhuri WadehraDepartment of Pathology and Laboratory Medicine, University of California, Los Angeles, 924 Westwood Blvd, Seventh Floor, Los Angeles, CA, 90095, USA.
Isaac YangDepartment of Neurosurgery, University of California, Los Angeles, 300 Stein Plaza, Los Angeles, CA, 90095, USA. iyang@mednet.ucla.edu.
University of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Using EMP2 for Image Guided Drug Delivery for Breast CancerR01CA163971 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI OLAFSEN, TOVE, WADEHRA, MADHURI · 2012 to 2016
$1.6M
PI3-Kinase activation and immunoresistance in gliomaF32CA132489 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI YANG, ISAAC · 2008 to 2008
$53k
NCI NIH HHS CA163971NCI NIH HHS F32 CA132489NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA163971
6 · The paper itself

Abstract

Epithelial membrane protein-2 (EMP2) expression is noted in many human cancers. We evaluated EMP2 as a biomarker in gliomas. A large tissue microarray of lower grade glioma (WHO grades II-III, n = 19 patients) and glioblastoma (GBM) (WHO grade IV, n = 50 patients) was stained for EMP2. EMP2 expression was dichotomized to low or high expression scores and correlated with clinical data. The mean EMP2 expression was 1.68 in lower grade gliomas versus 2.20 in GBMs (P = 0.01). The percentage of samples with high EMP2 expression was greater in GBMs than lower grade gliomas (90.0 vs. 52.6%, P = 0.001). No significant difference was found between median survival among patients with GBM tumors exhibiting high EMP2 expression and survival of those with low EMP2 expression (8.38 vs. 10.98 months, P = 0.39). However, EMP2 expression ≥2 correlated with decreased survival (r = -0.39, P = 0.001). The EMP2 expression level also correlated with Ki-67 positivity (r = 0.34, P = 0.008). The mortality hazard ratio for GBM patients with EMP2 score of 3 or higher was 1.92 (CI 0.69-5.30). Our findings suggest that elevated EMP2 expression is associated with GBM. With other biomarkers, EMP2 may have use as a molecular target for the diagnosis and treatment of gliomas.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorBrain NeoplasmsFemaleGene ExpressionGliomaHumansImmunohistochemistryKi-67 AntigenMaleMembrane GlycoproteinsMiddle AgedMolecular Targeted TherapyNeoplasm StagingBiomarkers, TumorEMP2 protein, humanKi-67 AntigenMembrane GlycoproteinsBiomarkerEpithelial membrane protein-2GlioblastomaGliomaPrognosis

Identifiers

PMID28887715
PMCPMC6118858
OpenAlexW2755548348

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.